NO330651B1 - Anvendelse av temozolomid til fremstilling av et preparat mot kreft - Google Patents

Anvendelse av temozolomid til fremstilling av et preparat mot kreft Download PDF

Info

Publication number: NO330651B1
Authority: NO; Norway
Prior art keywords: temozolomide; cancer; administered; preparation; day
Prior art date: 1999-03-30

Application number

NO20014725A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014725L (no

NO20014725D0 (no

Inventor

Mohamed H Ragab

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-30

Filing date

2001-09-28

Publication date

2011-05-30

2001-09-28 Application filed by Schering Corp filed Critical Schering Corp

2001-09-28 Publication of NO20014725D0 publication Critical patent/NO20014725D0/no

2001-11-13 Publication of NO20014725L publication Critical patent/NO20014725L/no

2011-05-30 Publication of NO330651B1 publication Critical patent/NO330651B1/no

Links

BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title claims description 37
229960004964 temozolomide Drugs 0.000 title claims description 37
206010028980 Neoplasm Diseases 0.000 title claims description 17
201000011510 cancer Diseases 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title claims description 10
125000004122 cyclic group Chemical group 0.000 claims description 6
208000003174 Brain Neoplasms Diseases 0.000 description 5
201000001441 melanoma Diseases 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
208000015634 Rectal Neoplasms Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
239000002111 antiemetic agent Substances 0.000 description 2
208000024055 brain glioblastoma Diseases 0.000 description 2
201000011609 brain glioblastoma multiforme Diseases 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
206010038038 rectal cancer Diseases 0.000 description 2
201000001275 rectum cancer Diseases 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940072698 ativan Drugs 0.000 description 1
229940088007 benadryl Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000035876 healing Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
238000000034 method Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
229940078646 other antiemetics in atc Drugs 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
-1 transdermal Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20014725A 1999-03-30 2001-09-28 Anvendelse av temozolomid til fremstilling av et preparat mot kreft NO330651B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28134899A	1999-03-30	1999-03-30
PCT/US2000/008079 WO2000057867A2 (fr)	1999-03-30	2000-03-27	Traitement du cancer ameliore avec le temozolomide

Publications (3)

Publication Number	Publication Date
NO20014725D0 NO20014725D0 (no)	2001-09-28
NO20014725L NO20014725L (no)	2001-11-13
NO330651B1 true NO330651B1 (no)	2011-05-30

Family

ID=23076905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014725A NO330651B1 (no)	1999-03-30	2001-09-28	Anvendelse av temozolomid til fremstilling av et preparat mot kreft

Country Status (18)

Country	Link
EP (1)	EP1165071B1 (fr)
JP (2)	JP2002540148A (fr)
CN (2)	CN1345240A (fr)
AR (1)	AR023185A1 (fr)
AT (1)	ATE310515T1 (fr)
AU (1)	AU780892B2 (fr)
BR (1)	BR0009380A (fr)
CA (1)	CA2368614C (fr)
DE (1)	DE60024243T2 (fr)
DK (1)	DK1165071T3 (fr)
ES (1)	ES2251987T3 (fr)
HK (1)	HK1044111B (fr)
HU (1)	HUP0200805A3 (fr)
NO (1)	NO330651B1 (fr)
NZ (1)	NZ536302A (fr)
TW (1)	TWI276434B (fr)
WO (1)	WO2000057867A2 (fr)
ZA (1)	ZA200107736B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100366249C (zh) *	2002-09-29	2008-02-06	天津帝士力投资控股集团有限公司	一种替莫唑胺控释给药系统
CN1742723A (zh) *	2004-09-02	2006-03-08	天津倍方科技发展有限公司	含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
CN1299772C (zh) *	2004-10-14	2007-02-14	孔庆忠	一种抗癌药物组合物
NZ554831A (en) *	2004-11-09	2009-10-30	Schering Corp	Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
ME02121B (fr) *	2006-01-17	2014-06-30	Abbvie Ireland Unlimited Co	Thérapie combinée comportant des inhibiteurs de PARP
SG10201500028RA (en) *	2006-04-05	2015-02-27	Opko Health Inc	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR061618A1 (es) *	2006-06-26	2008-09-10	Schering Corp	Formas de dosificacion unitaria de temozolomida
WO2008022535A1 (fr) *	2006-08-09	2008-02-28	Tian Jin Tasly Group Co., Ltd.	Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
JP5199263B2 (ja) *	2006-09-29	2013-05-15	シプラ・リミテッド	テモゾロミドと類似体を調製するための改善された方法
US20140005160A1 (en) *	2010-12-01	2014-01-02	Hooshmand SHESHBARADARAN	Method for Treating Refractory Cancer
CN102526038B (zh) *	2011-01-12	2013-09-11	北京人福军威医药技术开发有限公司	替莫唑胺的脑靶向药物组合物及其应用
CN107397735B (zh) *	2017-07-28	2020-07-10	东曜药业有限公司	一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) *	2023-11-24	2024-01-05	郑州德迈药业有限公司	一种替莫唑胺制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2233544A1 (fr) *	1995-10-04	1997-04-10	Schering Corporation	Combinaison temozolomide et interferon alpha pour le traitement du cancer avance
CA2184545A1 (fr) *	1996-07-31	1998-02-01	Pascale Reidenberg	Traitement du cancer a l'aide de temozolomide
CA2184546A1 (fr) *	1996-07-31	1998-02-01	Margaret H. Dugan	Methode pour le traitement d'asotrocytomes a forte incidence pediatrique, incluant le gliome du tronc cerebral

2000
- 2000-03-27 CN CN00805865A patent/CN1345240A/zh active Pending
- 2000-03-27 HK HK02103318.7A patent/HK1044111B/en not_active IP Right Cessation
- 2000-03-27 HU HU0200805A patent/HUP0200805A3/hu unknown
- 2000-03-27 BR BR0009380-7A patent/BR0009380A/pt not_active Application Discontinuation
- 2000-03-27 EP EP00918435A patent/EP1165071B1/fr not_active Expired - Lifetime
- 2000-03-27 CN CN2011100359769A patent/CN102160864A/zh active Pending
- 2000-03-27 ES ES00918435T patent/ES2251987T3/es not_active Expired - Lifetime
- 2000-03-27 DE DE60024243T patent/DE60024243T2/de not_active Expired - Lifetime
- 2000-03-27 AU AU39244/00A patent/AU780892B2/en not_active Ceased
- 2000-03-27 NZ NZ536302A patent/NZ536302A/en unknown
- 2000-03-27 JP JP2000607618A patent/JP2002540148A/ja active Pending
- 2000-03-27 AT AT00918435T patent/ATE310515T1/de active
- 2000-03-27 AR ARP000101370A patent/AR023185A1/es unknown
- 2000-03-27 DK DK00918435T patent/DK1165071T3/da active
- 2000-03-27 CA CA002368614A patent/CA2368614C/fr not_active Expired - Fee Related
- 2000-03-27 TW TW089105564A patent/TWI276434B/zh not_active IP Right Cessation
- 2000-03-27 WO PCT/US2000/008079 patent/WO2000057867A2/fr not_active Ceased
2001
- 2001-09-19 ZA ZA200107736A patent/ZA200107736B/xx unknown
- 2001-09-28 NO NO20014725A patent/NO330651B1/no not_active IP Right Cessation
2007
- 2007-03-20 JP JP2007073722A patent/JP2007169297A/ja active Pending

Also Published As

Publication number	Publication date
HK1044111A1 (en)	2002-10-11
AR023185A1 (es)	2002-09-04
CN1345240A (zh)	2002-04-17
DE60024243D1 (de)	2005-12-29
BR0009380A (pt)	2001-12-26
NO20014725L (no)	2001-11-13
HUP0200805A2 (hu)	2002-07-29
DE60024243T2 (de)	2006-08-17
CA2368614C (fr)	2008-07-22
NO20014725D0 (no)	2001-09-28
ES2251987T3 (es)	2006-05-16
HK1044111B (en)	2006-02-24
ATE310515T1 (de)	2005-12-15
WO2000057867A2 (fr)	2000-10-05
AU3924400A (en)	2000-10-16
NZ536302A (en)	2006-05-26
ZA200107736B (en)	2003-02-26
EP1165071B1 (fr)	2005-11-23
WO2000057867A3 (fr)	2001-04-19
JP2002540148A (ja)	2002-11-26
EP1165071A2 (fr)	2002-01-02
AU780892B2 (en)	2005-04-21
JP2007169297A (ja)	2007-07-05
TWI276434B (en)	2007-03-21
CA2368614A1 (fr)	2000-10-05
DK1165071T3 (da)	2006-02-20
CN102160864A (zh)	2011-08-24
HUP0200805A3 (en)	2004-07-28

Legal Events

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2015-10-26

MM1K

Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5939098A (en)	1999-08-17	Cancer treatment with temozolomide
Graham et al.	2015	How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly
JP2007169297A (ja)	2007-07-05	テモゾロミドを用いる改善された癌処置
ITMI972788A1 (it)	1999-06-17	Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
US6346524B1 (en)	2002-02-12	Cancer treatment with temozolomide
RU2010109359A (ru)	2011-10-20	Азитромицин для лечения кожных заболеваний
US20250288545A1 (en)	2025-09-18	Neostigmine combinations and compositions
Gupta et al.	1999	Intermittent short duration therapy with fluconazole is effective for tinea capitis
MXPA04010853A (es)	2005-02-14	Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer.
CA2184545A1 (fr)	1998-02-01	Traitement du cancer a l'aide de temozolomide
Llombart-Cussac et al.	1997	Docetaxel chemotherapy induces transverse superficial loss of the nail plate
WO2025092606A1 (fr)	2025-05-08	Application d'un médicament combiné de fumarate d'orbitazine et de témozolomide pour traiter le gliome cérébral
Miljković et al.	2018	The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura
MXPA01009926A (en)	2002-05-09	Improved cancer treatment with temozolomide
CA2893836A1 (fr)	2014-08-07	Combinaison medicamenteuse comprenant la phenylephrine et le paracetamol
Redding et al.	1992	A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection
US5942247A (en)	1999-08-24	Method for treating pediatric high grade astrocytoma including brain stem glioma
CA2229141A1 (fr)	1997-03-06	Therapie d'association pour des cancers avances comprenant le temozolomide et le cisplatine
ZA200207701B (en)	2004-02-10	Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug.
GB2510444A (en)	2014-08-06	Enhanced combination of phenylephrine and paracetamol
CN115381954B (zh)	2023-12-05	一种用于治疗骨肉瘤的联合用药物
US20240335424A1 (en)	2024-10-10	Compositions and methods for treating lipoma pain
US20120309847A1 (en)	2012-12-06	Dosing regimens and methods for treating or preventing promyelocytic leukemia
ITMI972170A1 (it)	1999-03-25	Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
Thomas	1979	Loxapine oral liquid concentrate in the treatment of young adult patients with acute schizophrenic symptoms.